{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 60,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a split-layout: left side focuses on clinical data (PK/PD/Safety), right side focuses on strategic positioning and clinical development plan.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/40",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population (MYD88MT)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75b25106-1676-4e3e-97df-b5c1400faee1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "PK and PD profiles in DL1-4 consistent with once every three-week dosing; KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos; common AEs were fatigue, cough, pyrexia; no DLTs observed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0beda51e-c78c-43e8-b488-d2d95747c5a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "Profound antitumor activity in preclinical models; Clinical strategy includes Monotherapy (MYD88MT DLBCL, PCNSL, WM) and Combinations with SOC agents.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bfa7ad4-7d20-4d16-bae0-930038738b6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "*DL1-3 have been completed and DL4 remains open to accrual. **AEs related to KT-413 were all Grade 1 and 2; SAEs (Gr. 4 sepsis and Gr. 4 lung infection) reported in one patient in DL3 occurred outside of the DLT window.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11ae2484-8920-4f6e-ab99-17f59746c059",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "Desired Translation of PK, PD and Safety of KT-413",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c4d1b1f-cd0d-4ad4-9c46-9b7003f3bbac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}